Dopastatin

Summary

Dopastatin (also called BIM-23A760 or similar chimeric analogs) is an experimental chimeric peptide combining somatostatin and dopamine pharmacophores. It was developed to overcome partial resistance to individual somatostatin analogs or dopamine agonists in acromegaly and prolactinoma, leveraging receptor heterodimerization for enhanced suppression of GH and prolactin. Multiple chimeric dopastatins (e.g., BIM-23A387, BIM-23A760) have been studied in preclinical and early clinical settings.

Mechanism of Action

Dopastatin compounds are chimeric molecules that simultaneously activate somatostatin receptors (primarily SSTR2 and SSTR5) and dopamine D2 receptors, thereby providing synergistic inhibition of growth hormone and prolactin secretion beyond what either class of agent achieves alone.

Routes of Administration

Goals & Uses

• Overcoming somatostatin analog resistancePharmacologicalModerate
• Prolactin suppressionEndocrineModerate
• Treatment of neuroendocrine tumorsOncologyLow
• Reduction of growth hormone hypersecretion in acromegalyEndocrineModerate

Contraindications

• Severe hepatic impairmentOrganModerateLiver function concerns
• PregnancyPopulationHighPotential fetal risk or insufficient safety data
• Hypersensitivity to somatostatin analogs or dopamine agonistsAllergy/ImmunologyHigh

Adverse Effects

• Injection site reactionsLocalCommon
• CholelithiasisHepatobiliaryUncommon
• Gastrointestinal disturbances (nausea, diarrhea, abdominal cramping)GastrointestinalCommon
• Orthostatic hypotensionCardiovascularUncommon
• Nausea and vomitingGastrointestinalCommon
• Hypoglycemia or hyperglycemiaMetabolicUncommon

Drug Interactions

• CyclosporineModerate
• Antidiabetic agents (insulin, sulfonylureas)Moderate
• Dopamine antagonists (e.g., haloperidol, metoclopramide)Moderate

Population Constraints

• Pediatric patientsAgeRelative
• Patients with Parkinson's disease on dopaminergic therapyNeurologicalRelative
• Elderly patients (>75 years)AgeRelative

Regulatory Status

• European UnionInvestigationalNo EMA approval; clinical investigations conducted in European centers.
• United StatesInvestigationalNo FDA approval; studied under IND/clinical trial frameworks for acromegaly.
• United KingdomInvestigationalNo MHRA approval; research/trial use only.

No regulatory approval in any jurisdiction as of current knowledge cutoff. Investigational use only; studied in Phase I/II clinical trials for acromegaly and neuroendocrine tumors.

Evidence & Sources

No sources recorded yet.